Successful management of lung adenocarcinoma with ALK/EGFR co-alterations and PD-L1 over-expression by bevacizumab combined with chemotherapy
| Autor: | Wendi Yang, Xiaoyue Zhang, Yuan Peng, Yusheng Huang, Zhenzhou Yang, Hengqiu He |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
Chemotherapy biology Bevacizumab Physiology medicine.drug_class business.industry medicine.medical_treatment Clinical Biochemistry medicine.disease Tyrosine-kinase inhibitor Targeted therapy hemic and lymphatic diseases PD-L1 medicine Cancer research biology.protein Adenocarcinoma Anaplastic lymphoma kinase Epidermal growth factor receptor business medicine.drug |
| Zdroj: | Angiogenesis. 25:5-8 |
| ISSN: | 1573-7209 0969-6970 |
| DOI: | 10.1007/s10456-021-09811-8 |
| Popis: | Anaplastic lymphoma kinase (ALK)/epidermal growth factor receptor (EGFR) co-alterations in adenocarcinomas are rare and no therapeutic consensus is reached. The potentially negative prognostic effects of programmed death-ligand 1 (PD-L1) expression on tyrosine kinase inhibitor (TKIs) efficacy further complicates the treatment options for patients with ALK/EGFR co-alterations and PD-L1 over-expression. We describe a case of advanced lung adenocarcinoma, harboring concurrent ALK/EGFR mutations and extremely high PD-L1 expression, that achieved sustained remission by the first-line treatment strategy of antiangiogenic therapy combined with chemotherapy. It is our firm conviction that the use anti-angiogenics should not have fallen out of favor in this era of targeted therapy and checkpoint inhibitors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink